Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_D87442600A32
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.
Journal
Journal of the Pediatric Infectious Diseases Society
Author(s)
Levy C., Werner A., Rybak A., Béchet S., Batard C., Hassid F., Desandes R., Frandji B., Ouldali N., Cohen R.
ISSN
2048-7207 (Electronic)
ISSN-L
2048-7193
Publication state
Published
Issued date
20/07/2024
Peer-reviewed
Oui
Volume
13
Number
7
Pages
371-373
Language
english
Notes
Publication types: Multicenter Study ; Letter ; Journal Article
Publication Status: ppublish
Abstract
After implementation of nirsevimab in 2023 in France as compared with 2022-2023, we found a 52.7%, 95% CI [46.4-58.9]) decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.
Keywords
Humans, France, Prospective Studies, Bronchiolitis/drug therapy, Infant, Male, Female, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/adverse effects, ambulatory, bronchiolitis, children, impact, nirsevimab
OAI-PMH
oai:serval.unil.ch:BIB_D87442600A32
DOI
10.1093/jpids/piae051
Pubmed
38779958
Web of science
001251774300001
Create date
27/05/2024 13:52
Last modification date
26/07/2024 6:02
Usage data